glp 1 agonist and weight loss Reduction with GLP-1 Agonists Paths for Discontinuation While Maintaining Weight GLP-1 and health: Beyond weight

Neoadjuvant Setting: Specifically, caution is advised for patients using GLP-1 RAs during neoadjuvant regimens like the phase 3 KEYNOTE-522 trial (NCT03036488)

There is no placebo group

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators (2022) Tirzepatide once weekly for the treatment of obesity

This includes hepatic steatosis, where 5% or more hepatocytes have macrovesicular steatosis in the absence of other causes of macrovascular steatosis in individuals who drink little or no alcohol, which is defined as less than 20 g/day for women and less than 30 g/day for men

The lowest effective dose isn't the lowest possible dose